Drug General Information (ID: DDIWHI79JT)
Drug Name			Ibritumomab tiuxetan		Drug Info		Idelalisib		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Pi3K Inhibitors

Mechanism of Ibritumomab tiuxetan-Idelalisib Interaction (Severity Level: Moderate)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Ibritumomab tiuxetan				Idelalisib
Mechanism		Diarrhea				Diarrhea
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Ibritumomab tiuxetan and Idelalisib

Recommended Action
Management		Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.

References
1	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.